SMC product assessment decisions

The Scottish Medicines Consortium (SMC) has announced its decision on the following therapies:

ACCEPTED FOR USE

  • Xolair (omalizumab) as add-on therapy in severe persistent allergic asthma.
  • Januvia (sitagliptin) for treatment of type II diabetes mellitus in combination with metformin.
  • Budenofalk (budesonide) for ulcerative colitis of the rectum and sigmoid colon.
  • Invanz (ertapenum) for prophylaxis of surgical site infection following elective colorectal surgery.
  • Atimos Modulite (formoterol) for coronary obstructive pulmonary disease.

REJECTED FOR USE

  • Cipralex (escitalopram) for obsessive compulsive disorder.
  • Prialt (ziconotide) for treatment of severe, chronic pain.
  • Cystadane (betaine) as adjunctive treatment of homocystinuria.

Further information: The Scottish Medicines Consortium

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

MIMS launches Respiratory and Allergy Learning workshops 2019

MIMS launches Respiratory and Allergy Learning workshops 2019

Join us for the MIMS Workshops Respiratory and Allergy...

Hormone Replacement Therapy (HRT)

Hormone Replacement Therapy (HRT)

Hormone doses and costs of HRT preparations.

Widespread false diagnosis of COPD is exposing patients to unnecessary medication risks, study suggests